BioSpace News Archive

Researchers within the School of Health and Kinesiology at the University of Nebraska at Omaha (UNO) have found that a novel antioxidant can provide a number of health benefits for individuals with peripheral artery disease.

DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that the Phase 2 CAPTIVE study evaluating treatment with DNX-2401 (tasadenoturev) and pembrolizumab in patients with recurrent glioblastoma (GBM) demonstrated a median overall survival of 12.5 months.

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission detailing the Company’s track record of successful developments and accomplishments within the oncology space as well as its commitment to evolving its Board of Directors (the “Board”) to drive shareholder value

BenevolentAI, announced today that baricitinib, a drug it first identified as a potential treatment for COVID-19 by the company has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA)

F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform the lives of patients with cancer through the development of innovative tetravalent mAb2 bispecific antibodies,

LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share.

Thermo Fisher Scientific Inc., the world leader in serving science, announced it has elected R. Alexandra “Alex” Keith to its board of directors.

According to the World Health Organization, half of the world’s children—approximately 1 billion children each year—are affected by physical, sexual or psychological violence that results in injuries, disabilities and death.

Today, the U.S. Food and Drug Administration approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older.

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders (the “Meeting”) being held on Tuesday, December 22, 2020 commencing at approximately 1:00 pm (MT).